Quality of life in children with acute lymphoblastic leukemia under chemotherapy: A review

  • Hadi Hayati School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran
  • Abbas Kebriaeezadeh Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Shekoufeh Nikfar Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Ali Ehsani Department of Pediatric Hematology and Oncology, School of Medicine AND Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Bahman Khosravi Department of Health Management and Economics, School of Health, Tehran University of Medical Sciences, Tehran, Iran
  • Mahdi Toroski Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  • Amin Hasanvand School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran
  • Bereket Molla Tigabu Department of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, International Campus, Haramaya University, Haramaya, Ethiopia
Keywords: Quality of life, Children, Lymphoblastic leukemia, Review

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children, often prevalent in children between the age of 2 and 6 years. However, it can lead to a loss of many years of life in these patients. Therefore, considering the importance of quality of life (QOL) for patients during treatment or after treatment discontinuation, and the extent of the therapeutic protocols, tools, and methods used to measure the QOL of children, we have undertaken a comprehensive review of the QOL of these patients.Methods: In designing a review of the outcomes, consultation with internal clinical experts was implemented first to identify relevant keywords and outcomes. We reviewed all English-language studies from 2000 to 2015 based on the Web of Science, PubMed, and Scopus databases.Results: 2621 studies were first identified in relevant electronic databases. However, only 10 studies met our inclusion criteria. Most of the selected studies used Health Utilities Index Mark 2 (HUI2) and 3 (HUI3) for assessing children's QOL. Some were interviewed by proxy, such as parents and even doctors and nurses involved in the treatment process. Most of the studies reported improvement of utility from 0.67% to 0.96% that in survivors varied from 0.71% to 0.94%.Conclusion: The results of this study illustrated that the treatment of patients with ALL in recent years has developed dramatically in different countries; and consequently, the QOL of these patients improved both during and after treatment.

References

(1) Alrudainy LA, Salih HM, Aldorky MK. Incidence and pattern of childhood leukaemia in Basrah, Iraq during 2003-2007. Iran J Blood Cancer 2009; 2(1): 11-7.

(2) Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004; 118-45.

(3) Rae C, Furlong W, Jankovic M, Moghrabi A, Naqvi A, Sala A, et al. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood. Eur J Cancer Care (Engl) 2014; 23(6): 779-85.

(4) Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354(2): 166-78.

(5) Conter V, Arico M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24(2): 255-64.

(6) Hertz RP, McDonald M, Kulig K. The burden of cancer in American adults. US: Outcomes Research Pfizer Global Pharmaceuticals 2005; 27.

(7) Farahmand M, Almasi A, Beigi M, Raee M, Azddari A. Epidemiology of childhood blood cancers, according to Fars cancer registry system. Journal of Shahed Uni 2011; 94: 27-34. [In Persian].

(8) Zareifar S, Almasi Hashiani A, Karimi M, Tabatabaee SH, Ghiasvand R. Five-year survival rate of pediatric leukemia and its determinants. Koomesh 2012; 14(1): 13-9. [In Persian].

(9) Hayati H, Kebriaeezadeh A, Ehsani MA, Nikfar S, Akbari Sari A, Troski M, et al. Systematic review of treatment costs for pediatrics acute lymphoblastic leukemia (Comparing clinical expenditures in developed and developing countries). Int J Pediatr 2016; 4(12): 4033-41.

(10) Hayati H, Kebriaeezadeh A, Ehsani MA, Nikfar S, Mehrvar A. Cost-analysis of treatment of pediatrics acute lymphoblastic leukemia based on ALL-BFM protocol. Int J Pediatr 2016; 4(9): 3381-9.

(11) van Litsenburg RR, Uyl-de Groot CA, Raat H, Kaspers GJ, Gemke RJ. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technology. Pediatr Blood Cancer 2011; 57(6): 1005-10.

(12) Furlong W, Rae C, Feeny D, Gelber RD, Laverdiere C, Michon B, et al. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59(4): 717-24.

(13) Zareifar S, Farahmandfar MR, Cohan N, Modarresnia F, Haghpanah S. Evaluation of health related quality of life in 6-18 years old patients with acute leukemia during chemotherapy. Indian J Pediatr 2012; 79(2): 177-82.

(14) Barr RD, Gonzalez A, Longchong M, Furlong W, Vizcaino MP, Horsman J, et al. Health status and health-related quality of life in survivors of cancer in childhood in Latin America: A MISPHO feasibility study. Int J Oncol 2001; 19(2): 413-21.

(15) Wright MJ, Galea V, Barr RD. Self-perceptions of physical activity in survivors of acute lymphoblastic leukemia in childhood. Human Kinetics Journals 2003; 15(2): 191-201.

(16) Cox CL, Lensing S, Rai SN, Hinds P, Burghen E, Pui CH. Proxy assessment of quality of life in pediatric clinical trials: Application of the Health Utilities Index 3. Qual Life Res 2005; 14(4): 1045-56.

(17) Fu L, Talsma D, Baez F, Bonilla M, Moreno B, Ah-Chu M, et al. Measurement of health-related quality of life in survivors of cancer in childhood in Central America: Feasibility, reliability, and validity. J Pediatr Hematol Oncol 2006; 28(6): 331-41.

(18) Hinds PS, Burghen EA, Zhou Y, Zhang L, West N, Bashore L, et al. The health utilities index 3 invalidated when completed by nurses for pediatric oncology patients. Cancer Nurs 2007; 30(3): 169-77.

(19) Fluchel M, Horsman JR, Furlong W, Castillo L, Alfonz Y, Barr RD. Self and proxy-reported health status and health-related quality of life in survivors of childhood cancer in Uruguay. Pediatr Blood Cancer 2008; 50(4): 838-43.

(20) Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355(15): 1572-82.

(21) Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27(14): 2328-38.

(22) Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford, UK: Oxford University Press; 2005.

Published
2018-06-23
How to Cite
1.
Hayati H, Kebriaeezadeh A, Nikfar S, Ehsani MA, Khosravi B, Toroski M, Hasanvand A, Tigabu BM. Quality of life in children with acute lymphoblastic leukemia under chemotherapy: A review. JPPM. 2(3/4):71-4.
Section
Review Article(s)